Literature DB >> 15531897

Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCT.

S Scholl1, L O Mügge, M Charbel Issa, C Kasper, K Pachmann, K Höffken, H G Sayer.   

Abstract

Dose-reduced allogeneic peripheral blood stem cell transplantation (PBSCT) is a therapeutic approach for patients with haematological malignancies who are not eligible for conventional allogeneic PBSCT. We analysed early development of lymphocyte subpopulations and the occurrence of cytomegalovirus (CMV) reactivation and acute graft-versus-host reaction (GvHD) in patients undergoing the protocol according to Slavin vs conventionally treated patients. Lymphocyte status prior to conditioning and at day +30 after allogeneic PBSCT was determined in 24 out of 51 patients who received conventional allogeneic PBSCT (eg cyclophosphamide plus total body irradiation) and compared with 27 patients being treated according to the Slavin protocol (fludarabine, busulphan and ATG). There is a significant delay in CD4 (T helper) cell development and consecutive lower CD4/CD8 ratios and a better reconstitution of CD8 (T cytotoxic) and NK (natural killer) cells after the Slavin protocol. Patients undergoing this protocol and no, or only grade I, acute GvHD show an even better NK cell reconstitution compared to patients with grade II-IV GvHD. A low CD4/CD8 ratio represents a CMV risk factor only in conventionally treated patients with grade 0-I GvHD, while after preparative regimen according to the Slavin protocol, the NK/CD8 ratio might be a marker for the prediction of CMV reactivation in addition to CMV risk status.

Entities:  

Mesh:

Year:  2005        PMID: 15531897     DOI: 10.1038/sj.bmt.1704752

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  4 in total

1.  Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation.

Authors:  Bipin N Savani; Stephan Mielke; Katayoun Rezvani; Aldemar Montero; Agnes S Yong; Laura Wish; Jeannine Superata; Roger Kurlander; Anurag Singh; Richard Childs; A John Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2007-08-24       Impact factor: 5.742

2.  A novel method to quantify and characterize leukemia-reactive natural killer cells in patients undergoing allogeneic hematopoietic stem cell transplantation following conventional or reduced-dose conditioning.

Authors:  Olaf Penack; Lars Fischer; Andrea Stroux; Chiara Gentilini; Axel Nogai; Arne Muessig; Susanne Ganepola; Thoralf Lange; Constanze Kliem; Olga Marinets; Igor Wolfgang Blau; Eckhard Thiel; Lutz Uhareka
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

Review 3.  The Role of NK Cells and Their Exosomes in Graft Versus Host Disease and Graft Versus Leukemia.

Authors:  Alireza Zafarani; Mahsa Taghavi-Farahabadi; Mohammad Hossein Razizadeh; Mohammad Reza Amirzargar; Mansoure Mansouri; Mohammad Mahmoudi
Journal:  Stem Cell Rev Rep       Date:  2022-08-22       Impact factor: 6.692

4.  Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab.

Authors:  Katie Matthews; ZiYi Lim; Behdad Afzali; Laurence Pearce; Atiyeh Abdallah; Shahram Kordasti; Antonio Pagliuca; Giovanna Lombardi; J Alejandro Madrigal; Ghulam J Mufti; Linda D Barber
Journal:  Haematologica       Date:  2009-06-02       Impact factor: 9.941

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.